 |
市场调查报告书
商品编码
1741546
全球吸入性药物市场按药物类别、产品类型、应用、分销管道和地区划分Global Inhalable Drugs Market, By Drug Class, By Product Type, By Application, By Distribution Channel, By Region |
||||||
价格
简介目录
2025 年全球可吸入药物市场规模估计为 400.6 亿美元，预计到 2032 年将达到 651.7 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 7.2%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 2025年的市场规模 | 400.6亿美元 |
| 效能数据 | 2020-2024 | 预测期 | 2025-2032 |
| 预测期：2025-2032年复合年增长率： | 7.20% | 2032年价值预测 | 651.7亿美元 |
吸入药物是一种可经由肺部从呼吸道局部给药以获得快速治疗效果的医疗物质。它们对治疗气喘、慢性阻塞性肺病和囊肿纤维化等肺部疾病特别有效。与从消化道口服给药相比，肺部为药物吸收提供了巨大的表面积。吸入药物绕过肝臟首过代谢，可将药物快速输送至肺组织并降低全身性药物浓度。与口服药物相比，主要优点包括数分钟内快速起效、剂量更低和副作用更少。常用的吸入药物包括用于气喘和慢性阻塞性肺病的支气管扩张剂（如沙丁胺醇）、皮质类固醇、可分散抗生素和胰岛素。随着全球肺部疾病数量的增加，吸入药物市场预计将继续稳定成长。
市场动态：
全球吸入性药物市场的发展受到气喘和慢性阻塞性肺病 (COPD) 等呼吸系统疾病全球盛行率上升的驱动。例如，根据世界卫生组织 (WHO) 2023 年 3 月 16 日的数据，慢性阻塞性肺病(COPD) 是全球第三大死因，2021 年气喘患者超过 3 亿，每年死于 COPD 的人数超过 300 万人。日益严重的污染和生活方式的改变导致肺部疾病病例不断增加。吸入性药物在治疗直接影响呼吸道的疾病方面具有卓越的疗效，这也为市场带来了益处。定量吸入器 (MDI) 和干粉吸入器 (DPI) 等药物传输设备的技术进步正在拓展新型疗法的机会。然而，吸入性药物开发和生产的高成本限制了更广泛市场的成长。此外，对肺部药物输送系统临床试验和产品核可的严格监管也是一个限制。然而，在预测期内，对先进配方和联合治疗的持续研究和开发可能会开闢新的途径。
本研究的主要特点
- 本报告对全球吸入药物市场进行了详细分析，并以 2024 年为基准年，提供了 2025 年至 2032 年预测期的市场规模和年复合成长率(CAGR)。
- 它还揭示了各个领域的潜在商机，并解释了该市场的有吸引力的投资提案矩阵。
- 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的主要考察。
- 它根据公司亮点、产品系列、关键亮点、财务业绩和策略等参数，对全球吸入性药物市场的主要企业进行了概述。
- 本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
- 全球吸入性药物市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进入者和金融分析师。
- 相关人员可以透过分析全球吸入药物市场所使用的各种策略矩阵来促进决策。
目录
第一章 研究目的与前提
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章市场动态、法规与趋势分析
- 市场动态
- 主要亮点
- 监管情景
- 近期动态
- PEST分析
- 波特分析
- 合併、收购和合作
4. 全球吸入性药物市场-冠状病毒（COVID-19）大流行的影响
- COVID-19流行病学
- 供需侧分析
- 经济影响
5. 2020-2032 年全球吸入药物市场（依药物类别）
- 吸入性皮质类固醇
- 白三烯调节剂
- 长效β受体拮抗剂（LABA）
- 长效毒蕈碱拮抗剂（LAMA）
- 其他的
6. 2020 年至 2032 年全球吸入性药物市场（依产品类型）
- 气雾剂
- 干粉配方
- 喷
- 其他的
7. 全球吸入性药物市场（按应用划分），2020 年至 2032 年
- 呼吸系统疾病
- 气喘
- 慢性阻塞性肺病（COPD）
- 囊肿纤维化
- 过敏性鼻炎
- 其他的
- 非呼吸系统疾病
8. 2020-2032 年全球吸入性药物市场（依分销管道）
- 医院药房
- 零售药局
- 网路药局
9. 2020-2032 年全球吸入药物市场（按地区）
- 北美洲
- 美国
- 加拿大
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 其他亚太地区
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东地区
- 非洲
- 北非
- 中部非洲
- 南非
第十章 竞争格局
- 公司简介
- GSK plc.
- Mundipharma International.
- Boehringer Ingelheim International GmbH.
- Cipla Inc.
- AstraZeneca
- Sanofi
- Vectura Group Ltd.
- Viatris Inc.
- 3M Health Care
- Allied Healthcare Products, Inc.
- CareFusion Corporation
- GF Health Products, Inc.
- Merck &Co., Inc.
- Novartis AG
- Omron Healthcare, Inc.
- Glenmark Pharmaceuticals
- PARI Respiratory Equipment, Inc.
第 11 章 章节
- 参考
- 调查方法
- 关于出版商
简介目录
Product Code: CMI6512
Global Inhalable Drugs Market is estimated to be valued at USD 40.06 Bn in 2025 and is expected to reach USD 65.17 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 40.06 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.20% | 2032 Value Projection: | USD 65.17 Bn |
Inhalable drugs are medical substances that can be administered locally through the respiratory tract via the lung for rapid therapeutic effects. They are particularly effective for treating lung conditions such as asthma, chronic obstructive pulmonary disease and cystic fibrosis. The lung provides huge surface area for drug absorption as compared to oral administration through the gastrointestinal tract. Inhalable drugs bypass hepatic first-pass metabolism for faster delivery of medications directly to the lung tissues and lower systemic levels. Some key advantages include rapid onset of action within minutes, lower dosing, and reduced side effects as compared to oral medications. Popular inhalable drugs include bronchodilators for asthma and chronic obstructive pulmonary disease like albuterol, corticosteroids, dispersible antibiotics, and insulin. With rising lung diseases globally, the inhalable drugs market is expected to grow steadily in the future.
Market Dynamics:
Global inhalable drugs market is driven by the growing prevalence of respiratory diseases such as asthma and COPD worldwide. For instance, on March 16, 2023, according to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, and over 300 Mn people suffered from asthma in 2021, while over 3 Mn people die each year from COPD. Increasing pollution levels and changing lifestyles have contributed to the rising caseload of lung illnesses. The market also benefits from the superior therapeutic efficacy of inhalable drugs in treating conditions, affecting the respiratory tract directly. Technological advancements in drug delivery devices such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) are expanding opportunities for novel therapies. However, high costs that are associated with development and production of inhalable drugs limit wider market growth. Additional constraints include stringent regulations around clinical trials and product approval for pulmonary drug delivery systems. Nevertheless, ongoing research and development (R&D) into advanced formulations and combination therapies could unlock new avenues over the forecast period.
Key features of the study:
- This report provides in-depth analysis of the global inhalable drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global inhalable drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include GSK plc, Mundipharma International., Boehringer Ingelheim International GmbH., Cipla Inc., AstraZeneca, Sanofi, Vectura Group Ltd, Viatris Inc, 3M Health Care, Allied Healthcare Products, Inc., CareFusion Corporation, GF Health Products, Inc., Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals and PARI Respiratory Equipment, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global inhalable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inhalable drugs market
Detailed Segmentation:
- Global Inhalable Drugs Market, By Drug Class
- Inhaled Corticosteroids
- Leukotriene modifiers
- Long-acting beta agonists (LABAs)
- Long-acting muscarinic antagonists (LAMAs)
- Others
- Global Inhalable Drugs Market, By Product Type
- Aerosol
- Dry powder Formulation
- Spray
- Others
- Global Inhalable Drugs Market, By Application
- Respiratory Diseases
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Allergic Rhinitis
- Others
- Non-respiratory Disease
- Global Inhalable Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Inhalable Drugs Market, By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- GSK plc.
- Mundipharma International.
- Boehringer Ingelheim International GmbH.
- Cipla Inc.
- AstraZeneca
- Sanofi
- Vectura Group Ltd.
- Viatris Inc.
- 3M Health Care
- Allied Healthcare Products, Inc.
- CareFusion Corporation
- GF Health Products, Inc.
- Merck & Co., Inc.
- Novartis AG
- Omron Healthcare, Inc.
- Glenmark Pharmaceuticals
- PARI Respiratory Equipment, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Inhalable Drugs Market, By Drug Class
- Global Inhalable Drugs Market, By Product Type
- Global Inhalable Drugs Market, By Application
- Global Inhalable Drugs Market, By Distribution Channel
- Global Inhalable Drugs Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Growing prevalence of respiratory diseases
- Risk of misuse of inhalable medicines
- Emergence of new drug delivery technologies
- Key Highlights
- Regulatory Scenario
- Recent Trends
- PEST Analysis
- PORTER's Analysis
- Mergers, Acquisitions, and Collaborations
4. Global Inhalable Drugs Market- Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Inhalable Drugs Market, By Drug Class, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Inhaled Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Leukotriene modifiers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Long-acting beta antagonists (LABAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Long-acting muscarinic antagonists (LAMAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
6. Global Inhalable Drugs Market, By Product Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Aerosol
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Dry powder Formulation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
7. Global Inhalable Drugs Market, By Application, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Respiratory Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Allergic Rhinitis
- Others
- Non-respiratory Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
8. Global Inhalable Drugs Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
9. Global Inhalable Drugs Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profile
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mundipharma International.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Strategies
- Vectura Group Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- 3M Health Care
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Allied Healthcare Products, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CareFusion Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GF Health Products, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Omron Healthcare, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- PARI Respiratory Equipment, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- Reference
- Research Methodology
- About us
